- History of prior rapidly accelerated fibrosarcoma or mitogen-activated protein kinase pathway inhibitor treatment - Palliative radiotherapy within 14 days prior to the first dose of study treatment - Major surgery or traumatic injury within 14 days prior to first dose of study treatment - Active malignancy other than melanoma that could potentially interfere with the interpretation of efficacy measures. Participants with a previous malignancy within the past 3 years are excluded except for participants with resected basal cell carcinoma or squamous cell carcinoma of the skin, melanoma in-situ, carcinoma in-situ of the cervix, and carcinoma in-situ of the breast - History of or evidence of retinal pathology on ophthalmological examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion, or neovascular macular degeneration - Uncontrolled glaucoma with intraocular pressure - Serum cholesterol ≥ Grade 2 - Hypertriglyceridemia ≥ Grade 2 - Hyperglycemia (fasting) ≥ Grade 2 - History of clinically significant cardiac dysfunction - Participants with active central nervous system (CNS) lesions (including carcinomatous meningitis) are excluded. However, participants are eligible if: • All known CNS lesions have been treated with stereotactic therapy or surgery, AND • There has been no evidence of clinical and radiographic disease progression in the CNS for ≥ 3 weeks after radiotherapy or surgery - Current severe, uncontrolled systemic disease - History of malabsorption or other condition that would interfere with absorption of study drugs - Pregnant, lactating, or breastfeeding women.